







an Open Access Journal by MDPI

Molecular Pathways in Cancers

Collection Editors:

Dr. Ion Cristóbal

Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, 28040 Madrid, Spain

Dr. Marta Rodríguez Moreno

1. Pathology Department, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain 2. Center for the Biomedical Research Network in Oncology (CIBERONC), E-28040 Madrid, Spain

Message from the Collection Editors

Dear Colleagues,

Despite continuous advances in anticancer therapies, the survival rates in most tumor types remain very poor, especially in those patients with advanced stages of the disease. There is a direct relationship between our level of understanding of each cancer's molecular pathogenesis and our capacity to develop novel and effective therapeutic strategies.

For this Topical Collection, we welcome contributions that improve our knowledge of the molecular alterations that deregulate key signaling pathways and govern tumor progression in highly prevalent human cancers. This Topical Collection will focus on studies that combine basic and translational research and provide significant findings with a clear, clinical, and therapeutic impact.

Dr. Ion Cristóbal Dr. Marta Rodríguez *Collection Editors*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us